VERU — VERU INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 863894 ·
Last close
$2.14
Market Cap
$36.49M
52W High
$7.33
52W Low
$2.03
ADV30
154,433
Next earnings
2026-12-17

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -7,713,681 -6,988,350 37,027,670 23,880,142 8,651,430
Mar 2026 0 — -7,218,968 -2,741,132 43,082,726 27,596,820 8,297,105
Dec 2025 0 — -5,424,015 -5,332,579 47,567,030 32,991,417 10,442,989
Sep 2025 0 — -7,459,363 1,453,507 29,835,719 15,794,562 11,503,049

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-26,042,991
Investing CF
$11,598,548
Financing CF
$23,314,431
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.18
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-332,357,975
Inventory
—
Receivables
—
ST Investments
$1,911,386
EBIT TTM
$-27,816,027
Pretax Income TTM
$-14,109,339
Interest Exp TTM
—
Analysts
3

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Sep 2025 0 -35,530,932 -22,726,279 29,835,719 11,503,049 18,332,670 -30,043,088
Sep 2024 0 -37,391,968 -37,801,426 60,418,772 28,102,060 32,316,712 -21,682,333
Sep 2023 16,296,958 -95,605,839 -93,152,692 50,023,091 30,344,930 19,678,161 -88,013,814
Sep 2022 39,354,352 -83,488,158 -84,040,618 135,358,450 52,561,133 82,797,317 -47,505,004

TTM Snapshot

Revenues TTM
$8,626,156
NetIncome TTM
$-13,608,554
OpCashFlow TTM
—
Assets (Latest)
$37,027,670
Forward EPS
$-0.98

Max Pain — expiry 2027-01-15

max pain strike: $3.00 · spot: $2.31 · call oi: 1,779 · put oi: 259
Expected Move to 2027-01-15: ±$0.95 (41.13%) — implied range $1.36 – $3.26 · ATM straddle on $2.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
CNTB Connect Biopharma Holdings Ltd $36.45M $0.58 —
SER Serina Therapeutics, Inc. $36.27M $1.37 —
GRCE Grace Therapeutics, Inc. $36.18M $1.72 —
BMEA Biomea Fusion, Inc. $35.47M $0.49 —
OSTX OS Therapies Inc $34.86M $0.74 —

News headlines (Yahoo Finance, 1h cache)

Veru Presents New Results at ObesityWeek 2026: GLP-1 Weight Loss in Older Adults Associated with Physical Function Decline; Adding Enobosarm Preserved Significant Lean Mass and Physical Function
2026-11-17 13:30 · Yahoo
Veru to Present New Results on Effects of Enobosarm on Physical Function in Older Patients Receiving GLP-1 RA from the Phase 2b QUALITY clinical study at ObesityWeek 2026
2026-11-09 13:30 · Yahoo
Veru (VERU) Q3 2026 Earnings Call Transcript
2026-08-17 11:58 · Yahoo
Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss
2026-08-04 12:30 · Yahoo
Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference
2026-07-30 12:30 · Yahoo
Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
2026-07-27 12:10 · Yahoo
Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day
2026-07-07 12:30 · Yahoo
Veru And 2 Other Intriguing Penny Stocks To Watch
2026-06-05 12:05 · Yahoo
Earnings call transcript: Veru Inc Q2 2026 shows improved financials
2026-06-01 04:08 · Yahoo
Veru Teams Up With Novo Nordisk for Obesity Combination Therapy Trial (VERU)
2026-06-04 14:22 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.